Latest News

Circassia’s Hay Fever Treatment Improves Patients’ Allergy Symptoms in Phase II Clinical Trial

Treatment Progresses into Final Phase II Clinical Study

27 September 2011

Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction in Allergy Symptoms During 12-Month Follow-up

Results Presented at Plenary Symposium of European Academy of Allergy and Clinical Immunology Congress

13 June 2011

Circassia Completes £60 Million ($98 Million) Fundraising For Final-Stage Development of Lead Allergy Products

19 April 2011

Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment from Airmid Inc

09 February 2011

Circassia ToleroMune T-cell Vaccine Achieves Significant Reduction in Allergy Symptoms in Key Phase II Clinical Study

Study Provides Proof-of-Concept for Commercial Formulation and Final Stage of Development

01 February 2011

Previous news articles

Did you know?

The average bed could be home to up to 1.5 million house dust mites